vs
Side-by-side financial comparison of CSP INC (CSPI) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $12.0M, roughly 1.1× CSP INC). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 0.8%, a 74.9% gap on every dollar of revenue. Xilio Therapeutics, Inc. produced more free cash flow last quarter ($-2.1M vs $-3.0M).
CSP Inc. is a U.S.-based technology firm offering cybersecurity solutions, managed IT services, high-performance computing systems, and IT consulting support. It serves enterprises across healthcare, finance, manufacturing, and public sectors in North America and select global markets.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
CSPI vs XLO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.0M | $13.7M |
| Net Profit | $91.0K | $10.4M |
| Gross Margin | 39.3% | — |
| Operating Margin | -0.9% | -86.5% |
| Net Margin | 0.8% | 75.7% |
| Revenue YoY | -23.2% | — |
| Net Profit YoY | -80.7% | 179.1% |
| EPS (diluted) | $0.01 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.0M | $13.7M | ||
| Q3 25 | $14.5M | $19.1M | ||
| Q2 25 | $15.4M | $8.1M | ||
| Q1 25 | $13.1M | $2.9M | ||
| Q4 24 | $15.7M | — | ||
| Q3 24 | $13.0M | — | ||
| Q2 24 | $13.1M | — | ||
| Q1 24 | $13.7M | — |
| Q4 25 | $91.0K | $10.4M | ||
| Q3 25 | $-191.0K | $-16.3M | ||
| Q2 25 | $-264.0K | $-15.8M | ||
| Q1 25 | $-108.0K | $-13.3M | ||
| Q4 24 | $472.0K | — | ||
| Q3 24 | $-1.7M | — | ||
| Q2 24 | $-185.0K | — | ||
| Q1 24 | $1.6M | — |
| Q4 25 | 39.3% | — | ||
| Q3 25 | 36.6% | — | ||
| Q2 25 | 28.8% | — | ||
| Q1 25 | 32.0% | — | ||
| Q4 24 | 29.1% | — | ||
| Q3 24 | 28.4% | — | ||
| Q2 24 | 35.0% | — | ||
| Q1 24 | 47.3% | — |
| Q4 25 | -0.9% | -86.5% | ||
| Q3 25 | -3.7% | -10.1% | ||
| Q2 25 | -7.9% | -177.7% | ||
| Q1 25 | -7.6% | -472.7% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -15.7% | — | ||
| Q2 24 | -5.5% | — | ||
| Q1 24 | 9.0% | — |
| Q4 25 | 0.8% | 75.7% | ||
| Q3 25 | -1.3% | -85.4% | ||
| Q2 25 | -1.7% | -196.0% | ||
| Q1 25 | -0.8% | -452.7% | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | -12.7% | — | ||
| Q2 24 | -1.4% | — | ||
| Q1 24 | 11.6% | — |
| Q4 25 | $0.01 | $-3.74 | ||
| Q3 25 | $-0.02 | $-0.11 | ||
| Q2 25 | $-0.03 | $-0.16 | ||
| Q1 25 | $-0.01 | $-0.18 | ||
| Q4 24 | $0.05 | — | ||
| Q3 24 | $-0.17 | — | ||
| Q2 24 | $-0.02 | — | ||
| Q1 24 | $0.16 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.9M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $44.8M | $35.3M |
| Total Assets | $69.2M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.9M | $137.5M | ||
| Q3 25 | $27.4M | $103.8M | ||
| Q2 25 | $26.3M | $121.6M | ||
| Q1 25 | $29.5M | $89.1M | ||
| Q4 24 | $30.7M | — | ||
| Q3 24 | $30.6M | — | ||
| Q2 24 | $28.9M | — | ||
| Q1 24 | $27.1M | — |
| Q4 25 | $44.8M | $35.3M | ||
| Q3 25 | $44.6M | $-8.1M | ||
| Q2 25 | $47.5M | $7.1M | ||
| Q1 25 | $47.5M | $10.7M | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $47.3M | — | ||
| Q2 24 | $48.1M | — | ||
| Q1 24 | $48.2M | — |
| Q4 25 | $69.2M | $154.7M | ||
| Q3 25 | $71.2M | $133.7M | ||
| Q2 25 | $66.8M | $133.8M | ||
| Q1 25 | $67.1M | $103.7M | ||
| Q4 24 | $67.5M | — | ||
| Q3 24 | $69.4M | — | ||
| Q2 24 | $66.8M | — | ||
| Q1 24 | $64.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $-2.0M |
| Free Cash FlowOCF − Capex | $-3.0M | $-2.1M |
| FCF MarginFCF / Revenue | -25.1% | -15.3% |
| Capex IntensityCapex / Revenue | 0.9% | 0.7% |
| Cash ConversionOCF / Net Profit | -32.04× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-2.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | $-2.0M | ||
| Q3 25 | $1.9M | $-17.5M | ||
| Q2 25 | $-3.3M | $-14.5M | ||
| Q1 25 | $1.9M | $29.0M | ||
| Q4 24 | $1.7M | — | ||
| Q3 24 | $-1.5M | — | ||
| Q2 24 | $2.4M | — | ||
| Q1 24 | $1.7M | — |
| Q4 25 | $-3.0M | $-2.1M | ||
| Q3 25 | $1.7M | — | ||
| Q2 25 | $-3.3M | $-14.9M | ||
| Q1 25 | $1.9M | $29.0M | ||
| Q4 24 | $1.7M | — | ||
| Q3 24 | $-1.5M | — | ||
| Q2 24 | $2.4M | — | ||
| Q1 24 | $1.6M | — |
| Q4 25 | -25.1% | -15.3% | ||
| Q3 25 | 11.5% | — | ||
| Q2 25 | -21.7% | -184.0% | ||
| Q1 25 | 14.5% | 988.3% | ||
| Q4 24 | 10.8% | — | ||
| Q3 24 | -11.7% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 11.9% | — |
| Q4 25 | 0.9% | 0.7% | ||
| Q3 25 | 1.6% | 0.0% | ||
| Q2 25 | 0.4% | 5.0% | ||
| Q1 25 | 0.1% | 0.8% | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | -32.04× | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.69× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.04× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSPI
| Products | $6.7M | 56% |
| Services | $5.3M | 44% |
XLO
Segment breakdown not available.
